393 related articles for article (PubMed ID: 38057451)
41. Challenges faced when identifying patients for combination immunotherapy.
Ernstoff MS; Gandhi S; Pandey M; Puzanov I; Grivas P; Montero A; Velcheti V; Turk MJ; Diaz-Montero CM; Lewis LD; Morrison C
Future Oncol; 2017 Aug; 13(18):1607-1618. PubMed ID: 28835114
[TBL] [Abstract][Full Text] [Related]
42. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
Melaiu O; Lucarini V; Giovannoni R; Fruci D; Gemignani F
Semin Cancer Biol; 2022 Feb; 79():18-43. PubMed ID: 32659257
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
[TBL] [Abstract][Full Text] [Related]
44. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
45. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
46. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
47. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
48. Immuno-oncology combinations: a review of clinical experience and future prospects.
Antonia SJ; Larkin J; Ascierto PA
Clin Cancer Res; 2014 Dec; 20(24):6258-68. PubMed ID: 25341541
[TBL] [Abstract][Full Text] [Related]
49. Frontiers in cancer immunotherapy-a symposium report.
Cable J; Greenbaum B; Pe'er D; Bollard CM; Bruni S; Griffin ME; Allison JP; Wu CJ; Subudhi SK; Mardis ER; Brentjens R; Sosman JA; Cemerski S; Zavitsanou AM; Proia T; Egeblad M; Nolan G; Goswami S; Spranger S; Mackall CL
Ann N Y Acad Sci; 2021 Apr; 1489(1):30-47. PubMed ID: 33184911
[TBL] [Abstract][Full Text] [Related]
50. Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
Surendran A; Jenner AL; Karimi E; Fiset B; Quail DF; Walsh LA; Craig M
J Pharmacol Exp Ther; 2023 Oct; 387(1):66-77. PubMed ID: 37442619
[TBL] [Abstract][Full Text] [Related]
51. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
53. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
54. Cancer immunotherapy: A need for peripheral immunodynamic monitoring.
Wang W; Xia X; Wu S; Guo M; Lie P; He J
Am J Reprod Immunol; 2018 Jun; 79(6):e12793. PubMed ID: 29288509
[TBL] [Abstract][Full Text] [Related]
55. Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.
Zheng R; Liu X; Zhang Y; Liu Y; Wang Y; Guo S; Jin X; Zhang J; Guan Y; Liu Y
Front Immunol; 2024; 15():1383978. PubMed ID: 38756774
[TBL] [Abstract][Full Text] [Related]
56. Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.
Yuan J; Khilnani A; Brody J; Andtbacka RHI; Hu-Lieskovan S; Luke JJ; Diab A; Marabelle A; Snyder A; Cao ZA; Hodi FS
Eur J Cancer; 2021 Nov; 157():493-510. PubMed ID: 34561127
[TBL] [Abstract][Full Text] [Related]
57. Combining Radiation with Immunotherapy: The University of Pennsylvania Experience.
Luo LY; O'Hara MH; Mitchell TC; Vonderheide RH; Wherry EJ; Minn AJ; Maity A
Semin Radiat Oncol; 2020 Apr; 30(2):173-180. PubMed ID: 32381296
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy combinations for the treatment of patients with solid tumors.
Bluthgen MV; Basté N; Recondo G
Future Oncol; 2020 Aug; 16(23):1715-1736. PubMed ID: 32501724
[TBL] [Abstract][Full Text] [Related]
59. Highlights into historical and current immune interventions for cancer.
Cole K; Al-Kadhimi Z; Talmadge JE
Int Immunopharmacol; 2023 Apr; 117():109882. PubMed ID: 36848790
[TBL] [Abstract][Full Text] [Related]
60. The role of radiotherapy in the age of immunotherapy.
Sato H; Demaria S; Ohno T
Jpn J Clin Oncol; 2021 Apr; 51(4):513-522. PubMed ID: 33561212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
